Hikma: FTSE 100 giant’s boss replaced by former chief after share price woes pharma The boss of FTSE 100 giant Hikma Pharmaceuticals will be replaced by the firm’s former top chief after the group’s share price dropped by nearly a quarter this year. Riad Mishlawi has exited his role as chief executive at Hikma, with executive chairman Said Darwazah to step into the post with “immediate effect”. It ends [...]
Hikma’s profit jumps as demand for generic medicines booms pharma Hikma Pharmaceuticals reported a strong financial performance for 2024, with revenue rising nine per cent to $3.13bn (£2.47bn) and operating profit up 67 per cent to $612m (£483m). Profit attributable to shareholders nearly doubled, reaching $359m (£284m), while earnings per share rose 88 per cent. The multinational pharmaceutical company that develops, manufactures, and markets a [...]
Hikma given shot in the arm by ‘excellent’ double-digit growth Business Pharmaceutical firm Hikma has hiked its dividend and raised its guidance having hailed an “excellent” first half of the year. The Jordanian-founded FTSE 100 pharma firm, which in June bolstered its injectables offering with the purchase of Danish rival Xellia, posted a double-digit revenue rise of 10 per cent, raking in $1.6bn (£1.3bn) in the [...]
Hikma bolsters US injectables offering with purchase of Danish competitor June 17, 2024 Hikma Pharmaceuticals has bolstered its US injectables capabilities with the purchase of several divisions of Danish competitor Xellia Pharmaceuticals.
Hikma: Pharma giant starts year strong as new product sales surge in key markets April 25, 2024 In 2023, the group became the second-largest pharmaceutical company in Middle East and North Africa by sales.
